If you regularly use cannabis, you might be hesitant to tell your doctor about it. But you may not realize that the drug may cause negative interactions — possibly dangerous ones — if you take prescription medications.

For instance, if you have had a knee or hip replacement, an artificial heart valve, or heart irregularities, you might have been given a prescription for warfarin, sold under the brand name Coumadin. It’s an anticoagulant, meaning it will help you avoid blood clots. But combining warfarin with cannabis can increase the risk of nosebleeds or excessive bruising.

Since recreational cannabis is illegal in Pennsylvania, doctors might not think to ask patients whether they use it. A new app created by Penn State researchers is designed to let both patients and doctors see whether prescription drugs could have dangerous interactions with cannabis. The app was created by Kent Vrana, chairman of the department of pharmacology, who said it had 1,000 users in its first two weeks.

CANN-DIR, which stands for cannabinoid drug interaction review, is free for anyone with a smartphone or a computer. The idea for the web app was born out of a 2020 paper that Mr. Vrana and his colleague, Paul Kocis, published on the most common drug interactions and how the body might handle competing drugs. As their capstone project, three undergraduate students at Penn State wrote the code for the app. It launched on March 22.

Advertise with us

CANN-DIR uses publicly available information from pharmaceutical sites and databases to check whether certain drugs metabolize in a similar way to cannabis. If both drugs compete for space to break down in the liver, one could stick around in the bloodstream longer, increasing its side effects.

Warfarin is one of the most commonly prescribed anticoagulants in the nation, but the new cannabis regulation landscape means not everyone on warfarin knows about this interaction. “I think there’s a need,” Mr. Vrana said. “We’re all about harm reduction.”

Sometimes, he said, patients are reluctant to mention to their doctors that they use street drugs, not realizing how dangerous the combinations can be. “What I hope is that it will contribute to reducing adverse outcomes,” Mr. Vrana said. In most cases, the doctor would not report the patient to law enforcement. “Most doctors just want to know what you’re doing.”

According to an update at the Pennsylvania Department of Health’s March 22 meeting, more than 740,000 patients and caregivers are registered with the Medical Marijuana Program, and Pennsylvania has over 1,700 approved practitioners with the Board. Medical cannabis sales have increased in the state since 2020.

Dr. Michael Lynch, an emergency physician and the medical director for the University of Pittsburgh Medical Center poison center, treats some patients who are part of the Medical Marijuana Program. He sees the app’s importance and relevance for both patients and clinicians to learn more about interactions among drugs they are prescribed.

Advertise with us

“The nature of medication and substance interactions is that they tend to be complicated,” he said. While some drug interactions are well established, researchers are still learning about all of cannabis’s effects.

As other states have legalized the drug, many people have become more open about using it. Dr. Antoine Douaihy, a professor of psychiatry and medicine at UPMC, a practicing psychiatrist, and a member of the Medical Marijuana Board, said this normalization has improved patient disclosure. Dr. Lynch also said that in his experience, patients feel comfortable discussing the substances they’re ingesting, and that decreased stigmatization of cannabis may play a part in this openness. But Dr. Douaihy cautions against swinging too far in the other direction.

“There’s a tendency among young people to say ‘marijuana is not a big deal. It doesn’t affect the brain.’ Which is really not true,” Dr. Douaihy said. Studies show cannabis impacts the developing adolescent brain, and many cannabis products, like CBD oil, are not FDA regulated, so it becomes more difficult to discern a product’s contents. And at the other end of the spectrum, interactions could affect older folks, some of whom are prescribed as many as eight medications. “The biggest issue is patient safety,” Dr. Douaihy said. “This is the whole reason for having the app.” CANN-DIR can bridge these gaps in education and communication.

All three experts said more research needs to be done to understand the complexity of how cannabis works in the body and interacts with other substances. “As availability of cannabis grows, any effect associated will become more common,” Dr. Lynch said. “I don’t think we fully understand all the implications of increased access to this drug.”

Mr. Vrana and his colleagues are already at work on a second version of the app. They’re hoping to make CANN-DIR more patient friendly, as well as be more upfront about when a certain interaction is dangerous, say, for warfarin there could be a red X and a ‘warning’ label.

Dr. Douaihy said there’s a need within the medical community itself for more education and information on interactions, and he stresses the importance of having more conversations—both physician to physician and with patients. “You want to ask patients very directly whether they are using any marijuana products…we need to be straightforward and honest about that. We need to make sure we put patient safety first.”